New sleeping pill may treat Alzheimer's

Share this article:

A new insomnia drug may be used for Alzheimer's and depression, according to its Japanese maker.

Takeda Pharmaceutical Co. Ltd., the Osaka-based drug manufacturer, could extend the use of Ramelteon -- a new sleeping pill to be released in the U.S. market in early fall -- to treat Alzheimer's disease and other illnesses. The new drug, which is in clinical trials in Japan and Europe, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain, which are critical in regulating the body's sleep-wake cycle.

The company filed for FDA approval for the drug last year and expects to gain approval with "non-scheduled drug" status, which means that no restrictions will be placed on how physicians prescribe the drug. It may start clinical development of the drug to treat Alzheimer's disease and depression after the pill's launch, the company announced.

Share this article:

More in News

Congressman requests briefing on nursing home five-star rating system

Congressman requests briefing on nursing home five-star rating ...

A leader in Congress has called for an evaluation of the nursing home five-star rating system in light of a recent New York Times article. Rep. Elijah Cummings (D-MD) requested ...

CMS: Discharge assessments must be completed when residents transfer to a non-certified ...

Skilled nursing facilities must complete a discharge assessment when a resident is transferred from a certified to a non-certified bed, even if both beds are in the same building, the Centers for Medicare & Medicaid Services emphasizes in a recent memorandum.

Focusing on a single word might improve nursing home residents' quality of ...

An affordable, easily implemented relaxation technique could improve nursing home residents' psychological well-being. It also could potentially boost their immune systems, according to recently published findings.